A Phase 1 study of KBP-5209 in patients with advanced solid tumors

Trial Profile

A Phase 1 study of KBP-5209 in patients with advanced solid tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Pirotinib (Primary)
  • Indications Breast cancer; Lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Sihuan Pharmaceutical Holdings Group
  • Most Recent Events

    • 02 Jun 2017 Results (n=23) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 29 Mar 2016 According to a Sihuan Pharmaceutical Holdings media release, enrollment in the first three cohort groups have been completed and the fourth cohort group is in progress.
    • 12 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top